Clinical Trial Update: Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating cord blood-derived CAR-NK cells targeting CD19 for refractory or relapsed B-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Cord blood-derived CAR-NK cells (CD19-targeted) (CAR-NK cells targeting CD19)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: B-cell Non Hodgkin Lymphoma | Phase 1 | Status: RECRUITING